Literature DB >> 30648453

Myeloid malignancies with somatic GATA2 mutations can be associated with an immunodeficiency phenotype.

Mansour Alfayez1, Sa A Wang2, Sarah A Bannon3, Dimitrios P Kontoyiannis4, Steven M Kornblau1, Jordan S Orange5, Emily M Mace5, Courtney D DiNardo1.   

Abstract

Germline mutations in GATA2 are associated with a complex immunodeficiency and cancer predisposition syndrome. Somatic GATA2mut in myeloid malignancies may impart a similar phenotype. We reviewed adult patients with a diagnosis of GATA2mut hematological malignancy who were referred to our HHMC for genetic testing, and identified to have somatic GATA2mut. Nine patients with a median age of 63 years were included. Six patients (66.7%) were males. Atypical CML and acute myeloid leukemia were the most common initial presentation. The median overall VAF was 47.14%. Monocytopenia was pronounced when the GATA2mut involved the C-terminal ZFD. GATA2 N-terminal ZFD mutations tend to be co-mutated with biCEBPAmut. Unlike germline GATA2 mutations, monocytopenia associated with somatic GATA2 mutations often resolved at remission. We concluded that similar to germline GATA2 mutations, a subset of somatic GATA2 mutations can impart a germline phenotype.

Entities:  

Keywords:  Emberger syndrome; GATA2; MonoMAC syndrome; immunodeficiency; pulmonary alveolar proteinosis

Year:  2019        PMID: 30648453     DOI: 10.1080/10428194.2018.1551535

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease.

Authors:  Rahul S Vedula; Matthew P Cheng; Christine E Ronayne; Dimitrios Farmakiotis; Vincent T Ho; Sophia Koo; Francisco M Marty; R Coleman Lindsley; Tyler D Bold
Journal:  Blood Adv       Date:  2021-01-12

Review 2.  Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes.

Authors:  Sushree S Sahoo; Emilia J Kozyra; Marcin W Wlodarski
Journal:  Best Pract Res Clin Haematol       Date:  2020-07-29       Impact factor: 3.020

3.  Integrative Genomic Analysis Reveals Cancer-Associated Gene Mutations in Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Tyrosine Kinase Inhibitor.

Authors:  Waner Wu; Na Xu; Xuan Zhou; Liang Liu; Yaxian Tan; Jie Luo; Jixian Huang; Jiayue Qin; Juan Wang; Zhimin Li; Changxin Yin; Lingling Zhou; Xiaoli Liu
Journal:  Onco Targets Ther       Date:  2020-08-25       Impact factor: 4.147

4.  Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes.

Authors:  Hussein A Abbas; Vakul Mohanty; Ruiping Wang; Yuefan Huang; Shaoheng Liang; Feng Wang; Jianhua Zhang; Yihua Qiu; Chenyue W Hu; Amina A Qutub; Monique Dail; Christopher R Bolen; Naval Daver; Marina Konopleva; Andrew Futreal; Ken Chen; Linghua Wang; Steven M Kornblau
Journal:  Front Oncol       Date:  2021-08-04       Impact factor: 6.244

5.  ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome.

Authors:  Robert R West; Katherine R Calvo; Lisa J Embree; Weixin Wang; Laura M Tuschong; Thomas R Bauer; Desiree Tillo; Justin Lack; Stephenie Droll; Amy P Hsu; Steven M Holland; Dennis D Hickstein
Journal:  Blood Adv       Date:  2022-02-08

6.  Multiple Simultaneous Infections With Nontuberculous Mycobacteria in the Setting of GATA2 Mutation and Myelodysplastic Syndrome.

Authors:  Hussam Tabaja; Kelsey L Jensen; Christina G Rivera; Anisha Misra; Rajiv K Pruthi; Paschalis Vergidis
Journal:  Open Forum Infect Dis       Date:  2022-06-28       Impact factor: 4.423

Review 7.  Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?

Authors:  Emery H Bresnick; Mabel M Jung; Koichi R Katsumura
Journal:  Blood Adv       Date:  2020-09-22

8.  [Targeted next-generation sequencing for the molecular diagnosis of patients with chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitor].

Authors:  W E Wu; X Zhou; N Xu; J X Huang; L Liu; Y X Tan; J Luo; J Y Qin; C X Yin; L L Zhou; X L Liu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.